These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23726600)

  • 1. Excellent results of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids in renal transplant recipients--4-year results.
    Yoshimura N; Ushigome H; Nobori S; Suzuki T; Sakai K; Koshino K; Okajima H; Okamoto M
    Transplant Proc; 2013 May; 45(4):1472-5. PubMed ID: 23726600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The beneficial effect of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids on CMV infection in renal transplant recipients.
    Yoshimura N; Ushigome H; Akioka K; Nobori S; Suzuki T; Sakai K; Okamoto M
    Clin Exp Nephrol; 2013 Feb; 17(1):127-33. PubMed ID: 23011290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness and safety of high-dose mizoribine on ABO-incompatible living related kidney transplantation using anti-CD20 and anti-CD25 antibodies without splenectomy: 3-year results.
    Yoshimura N; Ushigome H; Nobori S; Suzuki T; Sakai K; Koshino K; Nakamura T; Nakao T; Harada S; Ito T
    Transplant Proc; 2014; 46(2):391-4. PubMed ID: 24655971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of High-Dose Mizoribine Combined With Cyclosporine, Basiliximab, and Corticosteroids in Renal Transplantation: A Japanese Multicenter Study.
    Ushigome H; Uchida K; Nishimura K; Akioka K; Fukuda Y; Yuzawa K; Fujisawa M; Sugitani A; Ito SI; Nakatani T; Horimi T; Yoshimura N
    Transplant Proc; 2016 Apr; 48(3):794-8. PubMed ID: 27234738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excellent results with high-dose mizoribine combined with cyclosporine, corticosteroid, and basiliximab in renal transplant recipients: multicenter study in Japan.
    Nishimura K; Uchida K; Yuzawa K; Fukuda Y; Ichikawa Y; Akioka K; Fujisawa M; Sugitani A; Ito S; Nakatani T; Horimi T; Yoshimura N
    Transplant Proc; 2012 Jan; 44(1):147-9. PubMed ID: 22310601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
    Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M
    Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
    Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
    Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Japanese multicenter study of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroid in renal transplantation (the fourth report).
    Oshiro Y; Nakagawa K; Hoshinaga K; Aikawa A; Shishido S; Yoshida K; Asano T; Murai M; Hasegawa A
    Transplant Proc; 2013 May; 45(4):1476-80. PubMed ID: 23726601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose steroid maintenance for renal transplant recipients.
    Kishikawa H; Nishimura K; Soda T; Yamanaka K; Hirai T; Kyo M; Takeda M; Fujisawa M; Kokado Y; Ichikawa Y
    Transplant Proc; 2010 Dec; 42(10):4030-2. PubMed ID: 21168618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of serum uric acid levels in response to the conversion from mycophenolate mofetil to mizoribine in kidney transplant recipients.
    Ding X; Zhu X; Zhang Y; Zhang L; Cheng M; Yu Y; Xu L; Li G
    Transplant Proc; 2013; 45(1):190-3. PubMed ID: 23375297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Mizoribine Combined With Tacrolimus in Living Donor Kidney Transplant Recipients: 3-Year Results by a Chinese Single Center Study.
    Shi Y; Liu H; Chen XG; Shen ZY
    Transplant Proc; 2019 Jun; 51(5):1337-1342. PubMed ID: 31155174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
    Nishioka T; Yoshimura N; Ushigome H; Watarai Y; Nishimura K; Akioka K; Nakamura N; Kawakita M; Yuzawa K; Nakatani T
    Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of mizoribine with mycophenolate mofetil for Asian renal transplantation--a meta-analysis.
    Xing S; Yang J; Zhang X; Zhou P
    Clin Biochem; 2014 May; 47(7-8):663-9. PubMed ID: 24463228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients.
    Chadban S; Eris J; Russ G; Campbell S; Chapman J; Pussell B; Trevillian P; Ierino F; Thomson N; Hutchison B; Irish A; Woodcock C; Kurstjens N; Walker R;
    Nephrology (Carlton); 2013 Jan; 18(1):63-70. PubMed ID: 23110508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparative trial of mizoribine versus mycophenolate mofetil in combination with tacrolimus for living donor renal transplantation.
    Takahara S; Takahashi K; Akiyama T; Uchida K; Tanabe K; Amada N; Toma H
    Clin Exp Nephrol; 2013 Dec; 17(6):899-904. PubMed ID: 23430390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Mizoribine and Mycophenolate Mofetil With a Tacrolimus-Based Immunosuppressive Regimen in Living-Donor Kidney Transplantation Recipients: A Retrospective Study in China.
    Shi Y; Liu H; Chen XG; Shen ZY
    Transplant Proc; 2017; 49(1):26-31. PubMed ID: 28104150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial Effects of High-Dose Mizoribine on ABO-Incompatible Living-Related Kidney Transplantation: Two-Year Results by a Japanese Multicenter Study.
    Harada S; Nakamura T; Ushigome H; Akutsu N; Akioka K; Nakatani T; Yoshimura N
    Transplant Proc; 2017 Jun; 49(5):967-970. PubMed ID: 28583569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety.
    Kyllönen LE; Eklund BH; Pesonen EJ; Salmela KT
    Transplantation; 2007 Jul; 84(1):75-82. PubMed ID: 17627241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.